Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Denali Therapeutics Inc

Healthcare US DNLI

23.31USD
-0.18(0.77%)

Last update at 2026-06-18T20:35:00Z

Day Range

23.2124.65
LowHigh

52 Week Range

12.5823.77
LowHigh

Fundamentals

  • Previous Close 23.49
  • Market Cap3192.45M
  • Volume2518393
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-540.52998M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -418.77798M
  • Diluted EPS TTM-2.91

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -512.43800M -422.70500M -145.19400M -325.97000M -291.15600M
Minority interest - - - - -
Net income -512.54000M -422.77300M -145.22400M -325.99100M -290.58100M
Selling general administrative 97.10M 105.44M 103.35M 90.47M 79.06M
Selling and marketing expenses - - 16.73M - -
Gross profit -11.18300M -7.79500M 330.53M 108.46M 48.66M
Reconciled depreciation 14.81M 8.99M 18.64M 10.38M 8.59M
Ebit -512.43800M -501.87800M -196.69900M -340.74400M -304.34400M
Ebitda -497.62600M -492.88600M -179.97300M -330.36100M -295.75100M
Depreciation and amortization 14.81M 8.99M 16.73M 10.38M 8.59M
Non operating income net other - - - - 4.59M
Operating income -555.34200M -487.34100M -196.69900M -340.74400M -295.75100M
Other operating expenses 555.34M 487.34M 527.23M 449.21M 344.41M
Interest expense - - - 14.77M 13.19M
Tax provision 0.10M 0.07M -0.00600M 0.02M -0.57500M
Interest income 42.90M 64.64M 51.51M 14.77M 4.59M
Net interest income 42.90M 64.64M 45.04M 14.77M 4.59M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.10M 0.07M 0.03M 0.02M -0.57500M
Total revenue 0.00000M 0.00000M 330.53M 108.46M 48.66M
Total operating expenses 544.16M 487.34M 527.23M 449.21M 344.41M
Cost of revenue 11.18M 7.79M 16.73M - -
Total other income expense net 42.90M 64.64M 51.51M 14.77M 4.59M
Discontinued operations - - - - -
Net income from continuing ops -512.54000M -422.77300M -124.42900M -325.99100M -290.58100M
Net income applicable to common shares - - - -325.99100M -290.58100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1144.85M 1374.18M 1153.92M 1460.24M 1404.16M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 30.60M 29.93M 26.93M 36.10M 30.60M
Total liab 131.09M 144.50M 122.96M 417.81M 441.87M
Total stockholder equity 1013.76M 1229.68M 1030.95M 1042.43M 962.29M
Deferred long term liab - - - - -
Other current liab 85.47M 79.04M 61.24M 63.76M 47.71M
Common stock 1.89M 1.77M 1.71M 1.69M 1.55M
Capital stock 1.89M 1.77M 1.71M 1.69M 1.55M
Retained earnings -2051.52400M -1538.98400M -1116.21100M -970.98700M -644.99600M
Other liab - - - 0.86M 5.07M
Good will - - - - -
Other assets - - 0.00000M 13.40M 11.87M
Cash 205.33M 174.96M 127.11M 218.04M 293.48M
Cash and equivalents - - - - -
Total current liabilities 98.35M 102.21M 77.98M 363.92M 378.25M
Current deferred revenue - - - 290.05M 320.30M
Net debt -163.03800M -126.25300M -74.86500M -157.69400M -234.92300M
Short term debt 9.55M 12.03M 7.26M 7.32M 5.45M
Short long term debt - - - - -
Short long term debt total 42.29M 48.71M 52.24M 60.35M 58.55M
Other stockholder equity 3062.72M 2764.88M 2144.81M 2018.62M 1608.24M
Property plant equipment - - - 74.52M 69.61M
Total current assets 900.66M 864.44M 1064.14M 1372.32M 897.23M
Long term investments 98.32M 359.37M - 0.00000M 425.45M
Net tangible assets - - - 1042.43M 962.29M
Short term investments 662.55M 657.37M 907.40M 1118.17M 571.93M
Net receivables 2.18M 2.17M 2.70M - 1.23M
Long term debt - - - - -
Inventory - - 0.00000M - -
Accounts payable 3.33M 11.14M 9.48M 2.79M 4.78M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.68M 2.02M 0.64M -6.88600M -2.49900M
Additional paid in capital - - - - -
Common stock total equity - - - - 1.55M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -644.99600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 124.26M 24.74M 16.54M 13.40M 11.87M
Deferred long term asset charges - - - - -
Non current assets total 244.20M 509.74M 89.78M 87.92M 506.93M
Capital lease obligations 36.76M 48.71M 52.24M 60.35M 58.55M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 264.78M -88.75600M 48.70M -141.38700M -13.12600M
Change to liabilities - - - -32.18800M -11.95700M
Total cashflows from investing activities 255.28M -88.75600M 249.31M -141.38700M -21.62600M
Net borrowings -8.16800M -32.33800M 0.00000M - -
Total cash from financing activities 189.22M 484.30M 17.82M 310.67M 19.35M
Change to operating activities - - - 8.16M -8.45500M
Net income -512.54000M -422.77300M -145.22400M -325.99100M -290.58100M
Change in cash 31.90M 47.85M -90.93800M -75.43300M -213.66700M
Begin period cash flow 176.53M 128.68M 218.04M 294.98M 508.64M
End period cash flow 208.43M 176.53M 127.11M 219.54M 294.98M
Total cash from operating activities -412.60000M -347.69400M -357.99100M -244.71600M -211.38900M
Issuance of capital stock 189.25M 499.25M 0.00000M 296.21M 0.00000M
Depreciation 14.81M 8.99M 16.73M 10.38M 8.59M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - 19.35M
Other cashflows from financing activities 189.22M 17.39M 17.82M 14.46M 19.35M
Change to netincome - - - 94.92M 91.01M
Capital expenditures 9.50M 15.91M 12.94M 17.83M 8.50M
Change receivables - - - - -
Cash flows other operating - - - - -31.51100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -213.66700M
Change in working capital 0.15M 16.94M -289.92600M -24.03000M -20.41200M
Stock based compensation 99.63M 102.88M 108.10M 99.85M 85.25M
Other non cash items -14.65400M -53.72800M -47.66900M -4.92500M -2.98400M
Free cash flow -422.10200M -363.60600M -370.93000M -262.54900M -219.88900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DNLI
Denali Therapeutics Inc		 -0.18 0.77% 23.31 - - 3643.65 3.21 2843.16 86.48
NVO
Novo Nordisk A/S		 -0.33 0.76% 43.19 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 43.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.36 1.60% 451.63 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.01 0.33% 609.94 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc

161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Ryan J. Watts Ph.D. Co-Founder, Pres, CEO & Director 1976
Dr. Alexander O. Schuth M.D. Co-Founder, CFO, COO & Sec. 1973
Dr. Marc Tessier-Lavigne Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director 1960
Dr. Carole Ho M.D. Chief Medical Officer & Head of Devel. 1973
Mr. Steve Edward Krognes Treasurer & Director 1968
Mr. Tyler M. Nielsen Sr. VP of Corp. Fin. 1978
Dr. Dana Andersen Chief Technical and Manufacturing Officer NA
Mr. Joe Lewcock Chief Scientific Officer NA
Dr. Laura Hansen VP of Investor Relations NA
Mr. Chris Walsh Gen. Counsel NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.